AI Article Synopsis

Article Abstract

Respiratory infection of young infants results in increased morbidity and mortality compared to infection of adults. In spite of the significance of this health issue, our understanding of the immune response elicited in infants especially in the respiratory tract is highly limited. We developed a nonhuman primate model to probe the virus-specific antibody response in infants following infection with influenza virus. Infection of infants resulted in more pulmonary damage and higher viral loads compared to adults. While the systemic IgG antibody response was similar in infant and adult animals, the response in the upper respiratory tract of the infant was compromised. This lower response was associated with an increased prevalence of Treg cells and low levels of BALT. These data suggest a defect in the ability to produce effective virus-specific antibody responses at the local infection site is a contributor to increased pulmonary damage in the at-risk infant population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323840PMC
http://dx.doi.org/10.1016/j.virol.2014.12.007DOI Listing

Publication Analysis

Top Keywords

antibody response
12
nonhuman primate
8
systemic igg
8
igg antibody
8
influenza virus
8
virus infection
8
respiratory tract
8
virus-specific antibody
8
pulmonary damage
8
response
6

Similar Publications

Antibody dynamics in dogs submitted to different canine visceral leishmaniasis treatment protocols.

Rev Bras Parasitol Vet

January 2025

Programa de Pós-graduação em Medicina Veterinária, Laboratório de Doenças Parasitárias, Departamento de Medicina Veterinária Preventiva, Universidade Federal de Santa Maria - UFSM, Santa Maria, RS, Brasil.

This study evaluated dynamics of antibodies in dogs treated for canine visceral leishmaniasis (CVL). Twenty-one dogs naturally infected by Leishmania spp. were grouped based on the treatment protocol: G1 (n=4) received allopurinol; G2 (n=10) allopurinol with miltefosine; and G3 (n=7) allopurinol, miltefosine and Leish-Tec® vaccine.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder. Antiamyloid antibody treatments modestly slow disease progression in mild dementia due to AD. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays an important role in disease onset and progression.

View Article and Find Full Text PDF

The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.

Protein Cell

January 2025

State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China.

Antibody-drug conjugates (ADCs) represent a promising class of targeted cancer therapeutics that combine the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Despite their therapeutic potential, the use of ADCs faces significant challenges, including off/on-target toxicity and resistance development. This review examines the current landscape of ADC development, focusing on the critical aspects of target selection and antibody engineering.

View Article and Find Full Text PDF

Carbon dots in biosensing have advanced significantly, adding improvements to different detection techniques. In this study, an amperometric immunosensor for Salmonella Thyphimurium was designed using antibodies labeled with carbon dots (Cdots) from pequi almond (Caryocar brasiliensis). Cdots were synthesized by pyrolysis and characterized by FTIR, UV/fluorescence, electrochemistry, zeta potential, and transmission electron microscopy (TEM).

View Article and Find Full Text PDF

Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass.

Osteoporos Int

January 2025

Department of Internal Medicine, Severance Hospital, Endocrine Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-Ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Unlabelled: We investigated the efficacy of romosozumab in premenopausal women with low bone mass. Romosozumab substantially increased bone mineral density and trabecular bone score in these women, aligning with its proven therapeutic benefits for postmenopausal osteoporosis.

Purpose: Romosozumab, an anti-sclerostin antibody, is a promising anabolic agent that increases bone formation and decreases bone resorption.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!